The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
The Journal for ImmunoTherapy of Cancer (JITC) received its first impact factor of 8.374 on June 26, 2018. JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
Published in the annual Journal Citation Reports (JCR), the impact factor is a calculation determined on the number of 2017 citations accumulated for JITC manuscripts published in 2015 and 2016. Other journal metrics for JITC can be found on the journal website.
JITC seeks submissions to its Basic Tumor Immunology section
Edited by Cornelis J.M. Melief, MD, PhD, the Basic Tumor Immunology section publishes on topics that include Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.
Submit your manuscript today to the open access journal.
As a way to thank the dedicated society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, one article per SITC member is eligible for waived article processing charges through 2018. To take advantage of this $2,400 value member benefit, contact SITC at +1 414-271-2456 or JITCEditor@sitcancer.org for your member code prior to submission.
Basic Tumor Immunology
Clinical Trials Monitor
Clinical/Translational Cancer Immunotherapy
Guidelines and Consensus Statements
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Women diagnosed with breast cancer within 5 years postpartum (PPBC) have poorer prognosis than age matched nulliparous women, even after controlling for clinical variables known to impact disease outcomes. Through rodent modeling, the poor prognosis of PPBC has been attributed to physiologic mammary gland involution, which shapes a tumor promotional microenvironment through induction of wound-healing-like programs including myeloid cell recruitment. Previous studies utilizing immune compromised mice have shown that blocking prostaglandin synthesis reduces PPBC tumor progression in a tumor cell extrinsic manner...
Advances in immunotherapy utilizing immune checkpoint inhibitors (ICIs) have transformed the treatment landscapes of several malignancies in recent years. Oncologists are now tasked with extending these benefits to a greater number of patients and tumor types. Metastatic castration-resistant prostate cancer (mCRPC) infrequently responds to ICIs, while the cellular vaccine approved for mCRPC, sipuleucel-T, provides a 4-month survival benefit but does not produce clinical responses as monotherapy...
Current checkpoint immunotherapy has shown potential to control cancer by restoring or activating the immune system. Nevertheless, multiple mechanisms are involved in immunotherapy resistance which limits the clinical benefit of checkpoint inhibitors. An immunosuppressive microenvironment is an important factor mediating the original resistance of tumors to immunotherapy. A previous report by our group has demonstrated that local angiotensin II (AngII) predominantly exists in a tumor hypoxic microenvironment where hypoxic tumour cells produced AngII by a hypoxia-lactate-chymase-dependent mechanism...
This conference will bring together talented T cell-based scientists and will promote discussions/collaborations for therapeutic intervention in the setting of tumor immunology. Join Wolchok, Allison, Schreiber, June, Greenberg and more for this unique ...
REGISTER NOW: mskcc.org/cartcell Memorial Sloan Kettering Cancer Center invites you to attend Clinical Application of CAR T Cells taking place on March 14-15, 2019 at Zuckerman Research Center in New York City. For more information or to register, ...
Fight Colorectal Cancer is hosting a webinar on December 11th at 2p EST with Scott M. Weissman, the founder of Chicago Genetic Consultants, LLC, a private genetic counseling practice. He will be discussing the difference between Tumor and Germline testing ...
Avail Continuing Medical Education (CME) Credits @World Cancer Congress 2019 in Dubai, UAE on March 04-05, 2019
This Meeting will offer Continuing Medical Education (CME)/ Continuing Education (CE) certification/accreditation to basic scientists, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com